Diffusion-weighted imaging and loco-regional N staging of patients with colorectal liver metastases.

Eur J Surg Oncol

Division of Hepatobiliary and General Surgery, Department of Surgery, Humanitas Clinical and Research Center, Humanitas University, Rozzano, Milan, Italy. Electronic address:

Published: March 2019

AI Article Synopsis

  • Diffusion-weighted MRI (DWI) is useful for assessing rectal cancer staging and detecting colorectal liver metastases, with a focus on identifying lymph node (LN) metastases that affect prognosis and treatment.
  • A study evaluated the role of quantitative ADC measurement in categorizing LNs in patients with liver metastases, concluding that lower ADC values indicate metastatic LNs.
  • The findings suggest that an ADC cut-off of 1.48 x 10 mm/s effectively differentiates metastatic from benign LNs, showcasing good sensitivity and specificity in both LN and patient analyses.

Article Abstract

Introduction: Diffusion-weighted MRI (DWI) contributes to N staging of rectal cancers and diagnosis of colorectal liver metastases (CLM). About 15% of CLM patients have loco-regional lymph node (LN) metastases that impact prognosis and treatment strategy. This retrospective study is the first one to evaluate quantitative ADC measurement as a tool to identify metastatic LNs in patients with liver metastases from colorectal cancer.

Methods: All consecutive patients undergoing surgery for CLM between 2008 and 2015 were considered. Inclusion criteria were: intraoperative retrieval of at least one LN; LN ≥ 5 mm; DWI performed ≤2 months before surgery. The ADC and ADC (ADC/ADC) were computed by two radiologists for all the LNs.

Results: Among 555 patients operated for CLM, 32 met the inclusion criteria. Fifty-six LNs were analyzed and 28 were metastatic. ADC and ADC in metastatic LNs were lower than in benign LNs (ADC = 1.37 vs. 1.83 × 10 mm/s, p < 0.001; ADC = 1.26 vs. 1.73, p < 0.001). The optimal cut-off value for ADC was 1.48 x 10 mm/s (AUC = 0.85, p < 0.001, sensitivity/specificity/accuracy 79%/93%/86% in per LN-analysis and 94%/86%/91% in per-patient analysis). The optimal cut-off for ADC was 1.15 (AUC = 0.80, p < 0.001, sensitivity/specificity/accuracy 69%/93%/81% and 76%,93%/84%). Excellent inter- and intra-operators' agreements were observed.

Conclusion: In patients with CLM, ADC values < 1.48 x 10 mm/s can be postulated as a cut-off to distinguish metastatic LNs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2018.11.018DOI Listing

Publication Analysis

Top Keywords

liver metastases
12
colorectal liver
8
metastatic lns
8
inclusion criteria
8
adc adc
8
patients
5
adc
5
diffusion-weighted imaging
4
imaging loco-regional
4
loco-regional staging
4

Similar Publications

Hypointense Findings on Hepatobiliary Phase MR Images.

Radiographics

February 2025

From the Department of Radiology, Division of Abdominal Imaging, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905 (K.C.H., M.L.W., C.L.W., J.F., S.K.V.); Department of Medical Imaging, University of Ottawa, Ottawa, Ontario, Canada (K.C.H.); Department of Medical Imaging, Beaujon University Hospital, Clichy, France (M.R.); HT Medica, Madrid, Spain (A.L.); Department of Radiology, University of Vienna, Vienna, Austria (A.B.S.); Department of Radiology, Sun Yat Sen University, Guangzhou, China (J.W.); and Department of Radiology, Division of Abdominal Imaging, Mayo Clinic, Scottsdale, Ariz (A.C.S.).

Hepatobiliary (HB) contrast agents are increasingly valuable diagnostic tools in MRI, offering a wider range of applications as their clinical use expands. Normal hepatocytes take up HB contrast agents, which are subsequently excreted in bile. This property creates a distinct HB phase providing valuable insights into liver function and biliary anatomy.

View Article and Find Full Text PDF

FAP-targeted PET/CT imaging in patients with breast cancer from a prospective bi-center study: insights into diagnosis and clinic management.

Eur J Nucl Med Mol Imaging

January 2025

Department of Nuclear Medicine and Minnan PET Center, Xiamen Key Laboratory of Radiopharmaceuticals, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.

Purpose: To evaluate the diagnostic accuracy and clinical impact of fibroblast activation protein (FAP)-targeted PET/CT imaging in primary and metastatic breast cancer and compare the results with those of standard-of-care imaging (SCI) and [F]FDG PET/CT.

Methods: We prospectively analyzed patients with diagnosed or suspected breast cancer who underwent concomitant FAP-targeted PET/CT (radiotracers including either [Ga]Ga-FAPI-46 or [F]FAPI-42) and [F]FDG PET/CT scans from June 2020 to January 2024 at two medical centers. Breast ultrasound (US) imaging was performed in all treatment-naïve patients as SCI.

View Article and Find Full Text PDF

Radiomics-based Machine Learning Approach to Predict Chemotherapy Responses in Colorectal Liver Metastases.

J Anus Rectum Colon

January 2025

Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Objectives: This study explored the clinical utility of CT radiomics-driven machine learning as a predictive marker for chemotherapy response in colorectal liver metastasis (CRLM) patients.

Methods: We included 150 CRLM patients who underwent first-line doublet chemotherapy, dividing them into a training cohort (n=112) and a test cohort (n=38). We manually delineated three-dimensional tumor volumes, selecting the largest liver metastasis for measurement, using pretreatment portal-phase CT images and extracted 107 radiomics features.

View Article and Find Full Text PDF

Introduction: Functioning neuroendocrine tumors (NETs) that do not respond to standard therapies are commonly considered for Peptide Receptor Radionuclide Therapy (PRRT). The benefit of Lu-DOTATATE PRRT in patients with progressive metastatic NET was analyzed and survival in multi-organ involvement.

Methods: Forty-one patients with refractory, progressive, or advanced symptomatic NETs, with or without previous treatment modalities were studied.

View Article and Find Full Text PDF

To investigate the role of immunotherapy in the overall survival (OS) of gastrointestinal cancer patients who have liver metastases at the time of the primary site cancer diagnosis. Survival outcome was compared between groups with immunotherapy and groups without immunotherapy. Chemoimmunotherapy was associated with improved OS (hazard ratio [HR] 0.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!